Vaishali Deenadayalan, MD

Roswell Park Comprehensive Cancer Center

Latest Content

ASCO 2026 presentation on Giredestrant for ER+/HER2- metastatic breast cancer at Roswell Park Cancer Center.

Conferences

06/10/2026

ASCO 2026: Evaluating Giredestrant in First-Line ER+/HER2- Metastatic Breast Cancer

Vaishali Deenadayalan, MD

CT22-01-2023 - Medical professional analyzing upper gastrointestinal cancer research updates at Roswell Park, highlighting practice-changing advances in diagnosis and treatment.

General GI Cancer

01/23/2026

Practice-Changing Updates in Upper Gastrointestinal Cancers From ASCO GI 2026

Vaishali Deenadayalan, MD

HER2-positive breast cancer updates from SABCS 2023, featuring expert Vaishali Deenadayalan at Roswell Park, emphasizing advancements in treatment and research in oncology for improved patient outcomes.

HER2-Positive Breast Cancer

12/30/2025

Updates in HER2-Positive Breast Cancer From SABCS 2025

Vaishali Deenadayalan, MD

HER2-Positive Breast Cancer

12/19/2025

Evolving Treatment Paradigms in Advanced Breast Cancer: Key Trial Updates From SABCS 2025

Karissa Britten, MDVaishali Deenadayalan, MD

Malignant cell division illustration showing cancer cells attacking the human immune system and bloodstream, emphasizing oncology research and targeted cancer therapies.

Articles

07/28/2025

Management of Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory Disease

Vaishali Deenadayalan, MD